Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Retatrutide stories

Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Sep 29, 2026

Eli Lilly's retatrutide helps diabetes patients lose up to 21% body weight in late-stage trial

Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.

Sep 29, 2026·3 sources
00
Aug 12, 2026

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 2026·2 sources
00
Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00
Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 2026·2 sources
00

Top claims

  • ▪Novo Nordisk treatments available on Hims & Hers start at $149 per month for the Wegovy pill and $199 per month for the Wegovy injector pen
  • ▪Prior to the November 6, 2026 partnership, Hims & Hers patients had to leave the platform and navigate to LillyDirect to obtain Eli Lilly obesity drugs
  • ▪Leerink Partners analyst Michael Cherny described the November 6, 2026 agreement with Eli Lilly as a clear positive that completes Hims & Hers' effort to secure access to major GLP-1 drugmakers

Subtopics

Eli Lilly7Clinical trials4Zepbound4Drug Policy, Pricing & Approval3Novo Nordisk3Pharma3Weight loss drugs3Weight management3GLP-1 / Weight-Loss Medications2GLP-1 medications2GLP-1 receptor agonists2Bioethicists of life extension1Blood sugar & insulin1Clinical evaluation1Clinical Trial Design & Evaluation1Compounding pharmacies1Drug Approval and Clinical Trials1Drug pricing1Foundao1GLP-11Gray market injectables1Lifestyle, Wellness and Nutrition1Medicare1Obesity treatment1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories